Josef Zamecnik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Josef Zamecnik has a total of 213 co-authors. Here are the top co-authors by number of shared publications:
- Lenka Krskova
Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
19 shared publications - Chris Jones
Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom
10 shared publications - Christof M. Kramm
Division of Pediatric Hematology and Oncology, University Medical Center Göttingen, Göttingen, Germany
10 shared publications - David T.W. Jones
Hopp Children's Cancer Center Heidelberg (KiTZ)
10 shared publications - Dominik Sturm
Division of Pediatric Glioma Research, Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany
10 shared publications - Maura Massimino
Pediatric Oncology Unit Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy
10 shared publications
Latest Publications
- Open Access
Transcriptomic analysis reveals distinct expression patterns in focal cortical dysplasia
Objective: Focal cortical dysplasia (FCD) is a common cause of drug‐resistant epilepsy in children and adults and exhibits substantial clinical and histopathological heterogeneity. However, morphological classification alone does not fully explain variability in epileptogenicity, disease severity, or treatment response. Methods: We aimed to define molecular mechanisms underlying FCD heterogeneity using integrated transcriptomic and regulatory analyses. RNA and small RNA sequencing (RNA‐seq) were conducted on cortical tissue resected during epilepsy surgery from 66 patients with histopathologically confirmed FCD subtypes IA ( n = 17), IIA ( n = 25), and IIB ( n = 24), along with 15 postmortem cortical control samples. Differential expression and weighted gene coexpression network analysis were used to identify coordinated transcriptional programs, and microRNA (miRNA) profiling was integrated to assess posttranscriptional regulatory mechanisms. Integrative multivariate analyses (DIABLO and sparse partial least squares discriminant analysis) were used to evaluate subtype discrimination, and findings were validated using an independent RNA‐seq dataset. Results: FCD subtypes showed distinct but partially overlapping molecular profiles. FCD IA showed a comparatively subtle transcriptional profile, dominated by reduced expression of genes involved in cortical development, neuronal signaling, ion regulation, and metabolic stress. FCD IIA displayed a modest yet coherent molecular signature involving developmental and neuronal disruption, together with metabolic stress and autophagy. FCD IIB exhibited the most extensive transcriptional remodeling, including activation of antigen presentation pathways, complement activation, cytoskeleton reorganization, synaptic alterations, and extracellular matrix organization. Differential miRNA profiling identified shared miRNAs, including miR‐320 family, miR‐27a‐5p, miR‐142‐5p, and miR‐21‐5p, alongside subtype‐specific regulatory patterns. Integration of messenger RNA and miRNA data revealed concordant alterations, indicating that miRNA dysregulation may contribute to stabilization of subtype‐specific transcriptional states. Significance: These findings demonstrate that FCD is characterized by coordinated transcriptional and posttranscriptional network alterations that extend beyond morphological classification and may contribute to variability in epileptogenicity across subtypes.
Open AccessTranscriptomic analysis reveals distinct expression patterns in focal cortical dysplasia
Objective: Focal cortical dysplasia (FCD) is a common cause of drug‐resistant epilepsy in children and adults and exhibits substantial clinical and histopathological heterogeneity. However, morphological classification alone does not fully explain variability in epileptogenicity, disease severity, or treatment response. Methods: We aimed to define molecular mechanisms underlying FCD heterogeneity using integrated transcriptomic and regulatory analyses. RNA and small RNA sequencing (RNA‐seq) were conducted on cortical tissue resected during epilepsy surgery from 66 patients with histopathologically confirmed FCD subtypes IA ( n = 17), IIA ( n = 25), and IIB ( n = 24), along with 15 postmortem cortical control samples. Differential expression and weighted gene coexpression network analysis were used to identify coordinated transcriptional programs, and microRNA (miRNA) profiling was integrated to assess posttranscriptional regulatory mechanisms. Integrative multivariate analyses (DIABLO and sparse partial least squares discriminant analysis) were used to evaluate subtype discrimination, and findings were validated using an independent RNA‐seq dataset. Results: FCD subtypes showed distinct but partially overlapping molecular profiles. FCD IA showed a comparatively subtle transcriptional profile, dominated by reduced expression of genes involved in cortical development, neuronal signaling, ion regulation, and metabolic stress. FCD IIA displayed a modest yet coherent molecular signature involving developmental and neuronal disruption, together with metabolic stress and autophagy. FCD IIB exhibited the most extensive transcriptional remodeling, including activation of antigen presentation pathways, complement activation, cytoskeleton reorganization, synaptic alterations, and extracellular matrix organization. Differential miRNA profiling identified shared miRNAs, including miR‐320 family, miR‐27a‐5p, miR‐142‐5p, and miR‐21‐5p, alongside subtype‐specific regulatory patterns. Integration of messenger RNA and miRNA data revealed concordant alterations, indicating that miRNA dysregulation may contribute to stabilization of subtype‐specific transcriptional states. Significance: These findings demonstrate that FCD is characterized by coordinated transcriptional and posttranscriptional network alterations that extend beyond morphological classification and may contribute to variability in epileptogenicity across subtypes.
- Open Access
- 13 February 2026
- Published by Springer Nature in Virchows Archiv
- Vol. 488 (5) , 1067-1076
Clinicopathological features of CIC-rearranged sarcomas: a retrospective study including novel visceral locations and methylation profile analysis
CIC-rearranged sarcomas represent a distinct rare pathological entity within the spectrum of undifferentiated small round cell sarcomas. This single institution retrospective study investigates the histopathological, molecular, and clinical characteristics of a cohort of 14 CIC-rearranged sarcomas. These tumors were diagnosed in eight male and six female patients, with the age at initial diagnosis ranging from 8 to 67 years and a mean age of 23.7 years. Among the patients, three novel locations of CIC::DUX4 sarcomas were detected in the mesentery, pancreas, and pterygopalatine fossa. Genetically, we identified 12 cases as CIC::DUX4 sarcomas and two as sarcomas with CIC gene rearrangement detected by break-apart fluorescence in situ hybridization only. The most common gene translocation had a breakpoint located in exon 20 of the CIC gene and exon 1 of the DUX4 gene; this alteration was found in 83% of all CIC::DUX4 cases we identified. We also performed DNA methylation analysis on seven cases, which was proven to be a reliable method with high sensitivity for clustering CIC-rearranged sarcomas.
- 13 February 2026
- Published by Springer Nature in Virchows Archiv
- Vol. 488 (5) , 1067-1076
Open AccessClinicopathological features of CIC-rearranged sarcomas: a retrospective study including novel visceral locations and methylation profile analysis
CIC-rearranged sarcomas represent a distinct rare pathological entity within the spectrum of undifferentiated small round cell sarcomas. This single institution retrospective study investigates the histopathological, molecular, and clinical characteristics of a cohort of 14 CIC-rearranged sarcomas. These tumors were diagnosed in eight male and six female patients, with the age at initial diagnosis ranging from 8 to 67 years and a mean age of 23.7 years. Among the patients, three novel locations of CIC::DUX4 sarcomas were detected in the mesentery, pancreas, and pterygopalatine fossa. Genetically, we identified 12 cases as CIC::DUX4 sarcomas and two as sarcomas with CIC gene rearrangement detected by break-apart fluorescence in situ hybridization only. The most common gene translocation had a breakpoint located in exon 20 of the CIC gene and exon 1 of the DUX4 gene; this alteration was found in 83% of all CIC::DUX4 cases we identified. We also performed DNA methylation analysis on seven cases, which was proven to be a reliable method with high sensitivity for clustering CIC-rearranged sarcomas.
- Open Access
- 11 October 2025
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 64 (10) , e70085
Molecular Landscape of Pediatric Low‐Grade Gliomas: Insights From RNA ‐ NGS and Bioinformatic Analysis
Pediatric low‐grade gliomas (pLGG) are the most common group of childhood brain tumors. Genetic alterations in the RAS–RAF–mitogen‐activated protein kinase (MAPK) pathway are the molecular drivers in the vast majority of pLGG. A large proportion of pediatric pLGG are characterized by the presence of fusion genes. An institutional molecular analysis together with an RNA‐NGS study was performed to reveal LGG‐associated molecular alterations. In our cohort of pLGG patients, molecular alterations were identified in 318 out of 342 cases (92.9%) through a combination of RT‐PCR, Sanger sequencing, and NGS methodologies. Fusion events were independently called using three fusion callers: Archer Analysis 6.0 and/or 7.0, Arriba version 2.4, and STAR‐Fusion 24. Among these, STAR‐Fusion had the lowest sensitivity, detecting rearrangements in only 67% of fusion‐positive cases. In contrast, Arriba detected rearrangements in 97.77% of cases, while Archer detected rearrangements in 88.6% of cases. These findings highlight differences in detection efficiency among fusion callers, emphasizing the importance of tool selection in molecular diagnostics. The detection of fusion genes is very important for correct diagnosis, prognosis, and adequate targeted treatment.
- 11 October 2025
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 64 (10) , e70085
Open AccessMolecular Landscape of Pediatric Low‐Grade Gliomas: Insights From RNA ‐ NGS and Bioinformatic Analysis
Pediatric low‐grade gliomas (pLGG) are the most common group of childhood brain tumors. Genetic alterations in the RAS–RAF–mitogen‐activated protein kinase (MAPK) pathway are the molecular drivers in the vast majority of pLGG. A large proportion of pediatric pLGG are characterized by the presence of fusion genes. An institutional molecular analysis together with an RNA‐NGS study was performed to reveal LGG‐associated molecular alterations. In our cohort of pLGG patients, molecular alterations were identified in 318 out of 342 cases (92.9%) through a combination of RT‐PCR, Sanger sequencing, and NGS methodologies. Fusion events were independently called using three fusion callers: Archer Analysis 6.0 and/or 7.0, Arriba version 2.4, and STAR‐Fusion 24. Among these, STAR‐Fusion had the lowest sensitivity, detecting rearrangements in only 67% of fusion‐positive cases. In contrast, Arriba detected rearrangements in 97.77% of cases, while Archer detected rearrangements in 88.6% of cases. These findings highlight differences in detection efficiency among fusion callers, emphasizing the importance of tool selection in molecular diagnostics. The detection of fusion genes is very important for correct diagnosis, prognosis, and adequate targeted treatment.
- Open Access
- 29 August 2025
- Published by Elsevier in Pathology - Research and Practice
- Vol. 275, 156190
A case series of newly described rare mesenchymal tumors of the knee and the role of molecular testing in their histopathological diagnosis
- 29 August 2025
- Published by Elsevier in Pathology - Research and Practice
- Vol. 275, 156190
Open AccessA case series of newly described rare mesenchymal tumors of the knee and the role of molecular testing in their histopathological diagnosis
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Figure S2. A) Hazard ratio for progression or death according to clinical characteristics. B) Hazard ratio for death according to clinical characteristics. LGG: Low-grade glioma, HGG: High-grade glioma
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Figure S2. A) Hazard ratio for progression or death according to clinical characteristics. B) Hazard ratio for death according to clinical characteristics. LGG: Low-grade glioma, HGG: High-grade glioma
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S4. Other molecular alterations reported.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S4. Other molecular alterations reported.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Data S1. Definition of response, Description of response criteria used by sites to evaluate tumor response, Definition of extend of resection, Definition of extend of resection used by sites.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Data S1. Definition of response, Description of response criteria used by sites to evaluate tumor response, Definition of extend of resection, Definition of extend of resection used by sites.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S1. NTRK fusion type and histology.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S1. NTRK fusion type and histology.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Figure S1. Diagram of population patients.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Figure S1. Diagram of population patients.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S5. Method of NTRK fusion detection as reported by participating centers.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S5. Method of NTRK fusion detection as reported by participating centers.